Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions

Sahu, P; Donovan, C; Paudel, KR; Pickles, S; Chimankar, V; Kim, RY; Horvart, JC; Dua, K; Ieni, A; Nucera, F; Bielefeldt-Ohmann, H; Mazilli, S; Caramori, G; Lyons, JG; Hansbro, PM

Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions

Sahu, P Donovan, C Paudel, KR Pickles, S Chimankar, V Kim, RY Horvart, JC Dua, K Ieni, A Nucera, F Bielefeldt-Ohmann, H Mazilli, S Caramori, G Lyons, JG Hansbro, PM

Permalink

Publisher:: Frontiers Media SA
Publication Type:: Journal Article
Citation:: Frontiers in Oncology, 13

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (620.32 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sahu, P
dc.contributor.author	Donovan, C
dc.contributor.author	Paudel, KR
dc.contributor.author	Pickles, S
dc.contributor.author	Chimankar, V
dc.contributor.author	Kim, RY
dc.contributor.author	Horvart, JC
dc.contributor.author	Dua, K
dc.contributor.author	Ieni, A
dc.contributor.author	Nucera, F
dc.contributor.author	Bielefeldt-Ohmann, H
dc.contributor.author	Mazilli, S
dc.contributor.author	Caramori, G
dc.contributor.author	Lyons, JG
dc.contributor.author	Hansbro, PM
dc.date.accessioned	2023-09-27T05:33:29Z
dc.date.available	2023-09-27T05:33:29Z
dc.identifier.citation	Frontiers in Oncology, 13
dc.identifier.issn	2234-943X
dc.identifier.uri	http://hdl.handle.net/10453/172332
dc.description.abstract	<jats:p>Primary lung carcinoma or lung cancer (LC) is classified into small-cell or non-small-cell (NSCLC) lung carcinoma. Lung squamous cell carcinoma (LSCC) is the second most common subtype of NSCLC responsible for 30% of all LCs, and its survival remains low with only 24% of patients living for five years or longer post-diagnosis primarily due to the advanced stage of tumors at the time of diagnosis. The pathogenesis of LSCC is still poorly understood and has hampered the development of effective diagnostics and therapies. This review highlights the known risk factors, genetic and epigenetic alterations, miRNA biomarkers linked to the development and diagnosis of LSCC and the lack of therapeutic strategies to target specifically LSCC. We will also discuss existing animal models of LSCC including carcinogen induced, transgenic and xenograft mouse models, and their advantages and limitations along with the chemopreventive studies and molecular studies conducted using them. The importance of developing new and improved mouse models will also be discussed that will provide further insights into the initiation and progression of LSCC, and enable the identification of new biomarkers and therapeutic targets.</jats:p>
dc.language	en
dc.publisher	Frontiers Media SA
dc.relation	International Association for the Study of Lung Cancer Foundation
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1079187
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1175134
dc.relation.ispartof	Frontiers in Oncology
dc.relation.isbasedon	10.3389/fonc.2023.1260411
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights	This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	3202 Clinical sciences
dc.subject.classification	3211 Oncology and carcinogenesis
dc.title	Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions
dc.type	Journal Article
utslib.citation.volume	13
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	open_access	*
dc.date.updated	2023-09-27T05:33:28Z
pubs.publication-status	Published online
pubs.volume	13

Abstract:

Primary lung carcinoma or lung cancer (LC) is classified into small-cell or non-small-cell (NSCLC) lung carcinoma. Lung squamous cell carcinoma (LSCC) is the second most common subtype of NSCLC responsible for 30% of all LCs, and its survival remains low with only 24% of patients living for five years or longer post-diagnosis primarily due to the advanced stage of tumors at the time of diagnosis. The pathogenesis of LSCC is still poorly understood and has hampered the development of effective diagnostics and therapies. This review highlights the known risk factors, genetic and epigenetic alterations, miRNA biomarkers linked to the development and diagnosis of LSCC and the lack of therapeutic strategies to target specifically LSCC. We will also discuss existing animal models of LSCC including carcinogen induced, transgenic and xenograft mouse models, and their advantages and limitations along with the chemopreventive studies and molecular studies conducted using them. The importance of developing new and improved mouse models will also be discussed that will provide further insights into the initiation and progression of LSCC, and enable the identification of new biomarkers and therapeutic targets.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172332